<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-N90OOAMV</identifier><date>2019</date><creator>Kos, Špela</creator><creator>Serša, Gregor</creator><relation>documents/doc/N/URN_NBN_SI_doc-N90OOAMV_001.pdf</relation><relation>documents/doc/N/URN_NBN_SI_doc-N90OOAMV_001.txt</relation><format format_type="issue">1</format><format format_type="volume">23</format><format format_type="type">article</format><format format_type="extent">str. 34-39</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID_HOST">3256955</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-N90OOAMV</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">DNK vakcine</subject><subject language_type_id="slv">dostavni sistemi</subject><subject language_type_id="slv">imunogenost</subject><subject language_type_id="slv">tumorski antigeni</subject><title>DNA vaccines for cancer treatment</title><title>DNA vakcine za zdravljenje raka</title></Record>